TRAM wants to announce support and interactions with the following individuals and organizations.

• If you are interested in supporting TRAM or working with TRAM, please contact us here. 
• If you would like to make a donation to TRAM please contact the Stanford Medical Center Development Office.

• December 01, 2017: Protein Simple and Stanford TRAM and TASC begin an expanded collaboration to utilize single cell proteomic analysis for translational medical applications.  Previously, we have worked with Protein Simple using their PeggySue (Simple Western).  Now, the new technology, Milo, enables, quantitative protein analysis signals from individual cells.

• July 18, 2018:  Tianjin Huanhu Hospital and Stanford TRAM discussed scientific interactions through a joint conference.  Dr. Zhang Peilan and Dr. Felsher presented scientific findings summarizing recent advances in translational medicine research in the managements of Cancer and Stroke through a joint symposium.

• December 28, 2020:  Dr. George Tidmarsh, MD, PhD, Stanford MCHRI  with TRAM initiated support of a new graduate training program Translational Research.  The new mentored training program will include partnerships and interactions among multiple Stanford Departments, Institutes and Programs as well as interactions with Biotechnology Companies.  

• August 15, 2021: Emulate, Stanford TRAM and TASC established a collaboration to utilize organ on chip experiments for the in situ analysis of disease pathogenesis, therapeutic response and molecular diagnostics.  Future studies will be involve multiple investigator research projects.

• October 5, 2021:  The Asclepius Network and Stanford TRAM announce plans together to establish an advanced medical ecological system to support patients, doctors, institutions and scientists.   Asclepius has developed unique and innovative platforms that can greatly facilitate rapid medical translation. Their goal now will be to create together new smart medicines. There will be the opportunity for future medical research interactions through partnered research meetings and projects.  
•  
• December 7, 2021:  San Shen Biotechnology and Stanford TRAM plan to work together to build programs that support  translational medical research. Sanchen has developed novel approaches that will actualize the potential of novel therapeutics.  They plan to provide opportunities for new research and educational experiences for future leaders in medicine and science with a focus on applying integrated interdisciplinary approaches to solve complex problems.

• March 15, 2023:  The Stanford Center for Translational Research and Applied Medicine is delighted  to form a strategic collaboration with MixTrust to jointly explore the application of biological information in Web3 DID certification.  MixTrust is a decentralized one-stop service platform that focuses on the Web3 DeFi field built on artificial intelligence technology that integrates modules such as digital identity, decentralized encrypted wallet, Web3 social, and AI financial services supporting mainstream public chains such as Ethereum, Arbitrum, and Aptos.